Advanced glycation: An important pathological event in diabetic and age related ocular disease

British Journal of Ophthalmology

Volumn 85, Issue 6, 2001, Pages 746-753

  Stitt, A W ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; BIOCHEMISTRY; CATARACT; CHEMICAL REACTION; CORNEA DISEASE; CROSS LINKING; DIABETIC RETINOPATHY; ENZYME MECHANISM; EYE DISEASE; GLYCATION; HUMAN; KERATOPATHY; PATHOGENESIS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REACTION ANALYSIS; RETINA DISEASE; REVIEW; VITREOUS DISEASE;

AGING; ANIMALS; CATARACT; DIABETIC RETINOPATHY; ENZYME INHIBITORS; GLAUCOMA; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; MACULAR DEGENERATION; MAILLARD REACTION; MICE; RATS;

EID: 0034985014     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.85.6.746     Document Type: Review

References (143)

1. Pathogenic effects of advanced glycosylation endproducts: Biochemical, biologic, and clinical implications for diabetes and aging
2. Advanced glycation endproducts: Impact on diabetic complications
3. Alzheimer's disease - Synergistic effects of glucose deficit, oxidative stress and advanced glycation end-products
4. Nonenzymatic browning in vivo: Possible process for aging of long-lived proteins
5. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen
6. Age-related increase in an advanced glycation end product in penile tissue
7. Advanced glycation end products in human penis: Elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS
8. Immunohistochemical localisation of advanced glycation end products in pulmonary fibrosis
9. Atherogenesis and advanced glycation: Promotion, progression, and prevention
10. Elevated AGE-modified ApoB in the sera of euglycemic, normolipidemic patients with atherosclerosis
11. The Maillard reaction in aging, diabetes, and nutrition
12. Action des acides amines sur les sucres: Formation des melanoides par vole methodique
13. Inactivation of nutrients by heating with glucose
14. Significance of fructose-induced protein oxidation and formation of advanced glycation endproducts
15. Structure of carbohydrate of hemoglobin Alc
16. Role of nonenzymatic glycosylation in the development of the sequelae of diabetes mellitus
17. Glycation of skin collagen in type I diabetes mellitus. Correlation with long-term complications
18. Identification of carboxymethyllysine as a degradation product of fructoselysine in glycated protein
19. Pathways of formation of glycoxidation products during glycation of collagen
20. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose
21. The glyoxalase system: New developments towards characterisation of a metabolic pathway fundamental to biological life
22. Detection of D-glucose-derived pyrrole compounds during Maillard reaction under physiological conditions
23. Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline
24. Formation ofcrossline as a fluorescent advanced glycation end product in vitro and in vivo
25. Pentosidine: A molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia
26. Urinary pyrraline as a biochemical marker of non-oxidative Maillard reactions in vivo
27. Tobacco smoke is a source of toxic reactive glycation products
28. Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers
29. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy
30. Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration
31. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
32. Molecular identity and cellular distribution of advanced glycation endproduct receptors. Relationship of p60 to OST-48 and 80K-H membrane proteins
33. Characterization of the advanced glycation endproduct receptor complex in human vascular endothelial cells
34. Advanced glycation end products and their recognition by macrophage and macrophage-derived cells
35. Effects of advanced glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells
36. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells
37. Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells
38. A redox-triggered ras-effector interaction. Recruitment of phosphatidylinositol 3′-kinase to Ras by redox stress
39. Activation of the receptor for advanced glycation end products triggers a p21 (ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress
40. Advanced glycation endproducts stimulate the MAP-kinase pathway in tubulus cell line LLC-PK1
41. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and ageing complications
42. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease
43. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats
44. Modification of DNA by reducing sugars: A possible mechanism for nucleic acid aging and age-related dysfunction in gene expression
45. Analysis of microtubule-associated protein tau glycation in paired helical filaments
46. Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation
47. Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products
48. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes
49. Glycation of insulin in the islets of Langerhans of normal and diabetic animals
50. Risk factors for cortical, nuclear, and posterior subcapsular cataracts: The POLA study. Pathologies Oculaires Liees a l'Age
51. Epidemiology of age-related cataract
52. Formation of hydroxyl radicals in the human lens is related to the severity of nuclear cataract
53. UV-B as a pro-aging and pro-cataract factor
54. Diabetic cataract formation: Potential role of glycosylation of lens crystallins
55. The browning reaction of proteins with glucose
56. Immunochemical evidence for increased formation of advanced glycation end products and inhibition by aminoguanidine in diabetic rat lenses
57. The ageing lens
58. Maillard reactions in lens proteins: Methylglyoxal-mediated modifications in the rat lens
59. Protein crosslinking by the Maillard reaction: Dicarbonyl-derived imidazolium crosslinks in aging and diabetes
60. Alpha-crystallin as a molecular chaperone
61. The effect of copper on human and bovine lens and on human cultured lens epithelium enzymes
62. Pathophysiology of cataracts: Copper ion and peroxidation in diabetics
63. Transition metal-catalyzed oxidation of ascorbate in human cataract extracts: Possible role of advanced glycation end products
64. Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid
65. Aprospective study of cigarette smoking and risk of cataract in men
66. Diabetic keratopathy
67. Advanced Maillard reaction and crosslinking of corneal collagen in diabetes
68. Advanced glycation end products in diabetic corneas
69. Ageing of the human corneal stroma: Structural and biochemical changes
70. The inhibition of sugar-induced structural alterations in collagen by aspirin and other compounds
71. Vitamins and analgesics in the prevention of collagen ageing
72. Techniques for stiffening the cornea
73. Structural macromolecules and supramolecular organisation of the vitreous gel
74. Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy
75. Diabetic vitreopathy
76. Advanced glycation endproducts in vitreous: Structural and functional implications for diabetic vitreopathy
77. Abnormalities of human vitreous structure in diabetes
78. Bowman Lecture 1998. Diabetic retinopathy: Some cellular, molecular and therapeutic considerations
79. Advanced glycation endproducts (AGEs) co-localise with AGE-receptors in the retinal vasculature of diabetic and AGE-infused rats
80. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
81. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy
82. Amadori albumin in type 1 diabetic patients: Correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries
83. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas
84. The relationship of glycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster
85. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice
86. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
87. Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats
88. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model
89. Advanced glycation endproducts cause breakdown of the blood retinal barrier in normoglycaemic rats: Implications for barrier discruption during diabetic retinopathy
90. Increased serum levels of advanced glycation end-products and diabetic complications
91. Advanced glycation end products in children and adolescents with diabetes: Relation to glycemic control and early microvascular complications
92. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products
93. Advanced glycation endproducts accelerate calcification in microvascular pericytes
94. Growth modulation of retinal microvascular cells by early and advanced glycation products
95. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: Relevance to diabetic retinopathy
96. Advanced glycation end products increase retinal vascular endothelial growth factor expression
97. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells
98. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor
99. Age-related variation in the hydraulic conductivity of Bruch's membrane
100. Evolution of soft drusen in age-related macular degeneration
101. Human ocular drusen possess novel core domains with a distinct carbohydrate composition
102. Effects of increasing numbers of phagocytic inclusions on human retinal pigment epithelial cells in culture: A model for aging
103. Drusen as risk factors in age-related macular disease
104. Regional variation and age-related changes of lysosomal enzymes in the human retinal pigment epithelium
105. Correlation between autofluorescent debris accumulation and the presence of partially processed forms of cathepsin D in cultured retinal pigment epithelial cells challenged with rod outer segments
106. Pathogenesis of drusen in the primate
107. Lysosomal enzyme cytochemistry of human RPE, Bruch's membrane and drusen
108. N(epsilon)(carboxymethyl) lysin and the AGE receptor RAGE colocalize in age-related macular degeneration
109. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age
110. The advanced glycation endproduct pentosidine induces the expression of PDGF-B in human retinal pigment epithelial cells
111. Development of a polyclonal antibody with broad epitope specificity for advanced glycation endproducts and localization of these epitopes in Bruch's membrane of the aging eye
112. Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells
113. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease
114. Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease
115. Is amyloid beta-protein glycated in Alzheimer's disease?
116. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina
117. The relationships of age changes in retinal pigment epithelium and Bruch's membrane
118. Experimental induction of AGEs in fetal L132 lung cells changes the level of intracellular cathepsin D
119. Advanced glycated albumin impairs protein degradation in the kidney proximal tubules cell line LLC-PK1
120. Accumulation of pyrraline-modified albumin in phagocytes due to reduced degradation by lysosomal enzymes
121. The formation of autofluorescent granules in cultured human RPE
122. Biochemical basis of lipofuscin, ceroid, and age pigment-like fluorophores
123. The epidemiology of open-angle glaucoma: A review
124. Changes in the collagenous matrix of the aging human lamina cribrosa
125. Effect of aminoguanidine on optic-nerve involvement in experimental diabetic rats
126. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking
127. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit
128. Aminoguanidine prevents regional blood flow increases in streptozotocin-diabetic rats
129. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin induced rat
130. Mechanistic studies Of advanced glycosylation endproduct inhibition by aminoguanidine
131. The effect of aminoguanidine on the blood retinal barrier in streptozotocin induced diabetic rats
132. Advanced glycosylation end products in diabetic renal and vascular disease
133. Aminoguanidine-mediated inactivation and alteration of neuronal nitric-oxide synthase
134. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation
135. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions: Mechanism of action of pyridoxamine
136. A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes
137. Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix
138. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
139. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation
140. Breakers of advanced glycation end products restore large artery properties in experimental diabetes
141. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness